dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo- [3,4-b] pyridin-6-yl]-4-oxo-3-quinoline carboxylic acid hydrochloride) , [Figure1.b] is new, fourth generation fluoroquinolone with broaden spectrum of antibacterial activity [4] [5] [6] . Moxifloxacin in combination with the 3 rd generation cephalosporine cefixime shows great additive and Synergistic effect to treat infectious diseases caused by a Gram-positive or Gram-negative pathogen like Streptococcus pneumoniae, Pseudomonas aeruginosa and Staphylococcus aureus [7] [8] . The Innovative tablet combination of Cefixime trihydrate and moxifloxacin was recently approved by DCGI and CDSCO. The present investigation carried out on tablet mixture prepared from commercially available individual tablet dosage form of above mentioned drugs. Literature survey shows that various analytical methods have been reported for estimation of cefixime [9] [10] [11] [12] and moxifloxacin [13] [14] [15] [16] [17] individually and combination with other drugs [18] [19] [20] [21] . Only one UV-Visible Spectrophotometric method 22 was reported for its simultaneous estimation. HoweverthereisnoRP-HPLC method reported for the simultaneous estimation of these drugs in combined dosage forms. In this communication, a simple, precise, reproducibleand accuratereversephase high performance liquid chromatographic method to estimate cefixime and moxifloxacin in tablet dosage for misreported.
MATERIAL AND METHODS

Chemicaland Reagents
The gratis samples of Cefixime (CEF)and Moxifloxacin (MOX) were obtained from Alembic limited, Vadodara and Torrent Pharmaceutical Industries Ltd., Ahmedabad. HPLC grade water and acetonitrile were purchased from E.Merck (India) Ltd., Mumbai. Potassiumdi hydrogen phosphate and orthophosphoric acid of ARGrade were obtained from S.D. Fine Chemicals Ltd., Mumbai.The marketed tablet formulations Suprax®having 400 mg of CEF from Lupin, Mumbaiand Moxif®having 400mg MOX from TorrentPharmaceuticalIndustriesLtd., Ahmedabad were purchased from the local market.
Chromatographicconditions
Theanalysisofthedrug wascarriedoutona Waters HPLC systeme quipped with a reverse phase PurospherBDSC18 column (250mm ×4.6mmid, 5µm particlesize), 2695 binary pump, a20µl injection loop and a 2487dual absorbace detect or and running on Waters Empower software.
Standard preparation Standard stock solution
Standard stock solutions were prepared by dissolving separately 100 mg of each drug in 100 ml of diluent which was a mixture of acetonitrile and phosphate buffer in the ratio of 40:60v/v to get concentration of 1000µg/ml.
Working standard solution
Working standard solutions were prepared by taking dilutions ranging from 20-120µg/ml for both CEF and MOX, respectively.
Validation of the method
The developed method was validated as per ICH guidelines [21] in terms of specificity, linearity, accuracy, precision, limits of detection (LOD) and quantification (LOQ) and system suitability. The accuracy was expressed in terms of percent recovery of the known amount of the active pharmaceutical ingredient in presence of excipients. The precision (%relative standard deviation, %RSD) was expressed with respect to the intraday and interday variation in the expected drug concentrations. Minor changes in pH of the mobile phase, flow rate, column temperature and detector wavelength were studied to evaluate the robustness of the developed assay method.
RESULTS AND DISCUSSION
Optimization of the method
The goal of this study was to develop a single isocratic phase HPLC method for the simultaneous determination of cefixime trihydrate and moxifloxacin.During optimizing the method some important parameters like pH of the mobile phase , concentration of the acid or buffer solution, percentage and type of the organic modifier, etc.,were tested for a good chromatographic separation. Trials showed that a slightly acidic with reverse phase, aPurospher BDSC18 column gives symmetric and sharp peaks. For this reason,0.01M potassium di hydrogen orthophosphate solution was preferred as an acidic buffer .When triethylamine was used as modifier the method shows a very good resolution between CEF and MOX at pH in the range of six .Finally acetonitrile andpotassium di hydrogen phosphate buffer pH6 with intheratioof40:60 v/v was selected as optimal for obtaining well defined and resolved peaks. The detection of thed rug was monitored at276nm. Theruntime was set at 10min. Under these optimized chromatographic conditions the retention time obtained for the drugscefixime and moxepril Figure 2 ]
Method validation
The developed method was validated as per ICH guidelinesin terms of specificity, linearity, accuracy, precision, limits of detection (LOD) and quantification (LOQ) and system suitability.
System suitability test
The system suitability test performed according to ICH guidelines. The observed RSD values at 1% level of analyte concentration were well within the usually accepted values (≤ 2%). Theoretical plates, tailing factor, resolution between CEF and MOX were determined for both assay and dissolution. The results are all within acceptable limits summarized in [Table1].
Specificity
The specificity of the method was checked for the interference of impurities in the analysis of a blank solution (without any sample) and then a drug solution of 20 µg/mL was injected into the column, underoptimized chromatographic conditions, to demonstrate the separationo f both CEF andMOX from any of the impurities, if present. As the rewasno interference of impurities and also no change in there tention time,the method was found to be specificand also confirmed with theresults of analysis of formulation.
Linearity study
The peak areas of CEF and MOX were linear with respect to the concentrations over the range of 20-120µg/mL for both respectively. 
Limit of detection and Limit of quantification
The linearity for CEF and MOX were performed from 20-120µg/ml. Linearity graph was plotted and the correlation coefficient (R 2 ) determined. The limit if detection (LOD) was calculated from the linearity curve using the formula LOD= 3.3× {Residual Standard deviation/Slope}.
The LOD for CEF was confirmed to be 0.5µg/mL and for MOX it was confirmed to be0.82 µg/ml.
The Limit of quantification (LOQ) was calculated from the linearity curve using the formula.
LOQ= 10× {Residual Standard deviation/Slope}
The LOQ for CEFwas confirmed to be2µg/ mL and forMOX it was confirmed to be2.5 µg/ml.
Precision
Intraday and Interday precision were evaluated by determining the corresponding responses three times on the same day and on 3 different days for CEF and MOX(40,60,80 µg/ ml).The results of intra-and inter-day variations are shown in [Table3]. The results obtained from intermediate precision also indicated a good method precision. All the data were within the acceptance criteria.
Accuracy
The accuracy of the method was determined by recovery experiments. It was confirmed by studying the recovery at three different concentrations, 50%, 100%,and 150% of those expected by spiking a previously analyzed test solution with additional drug standardsolutions, the analysis being done inreplicate. The %RSD and %relative error in allcases were within the acceptable limit (≤2%). Itis evident fromtheresults of accuracy study, reported in [ Table 4 ] that the proposed method enablesvery accurate quantitative simultaneous estimation of CEF and MOX
Robustness and Ruggedness
Robustness studies were carried out after deliberate alterations of flow rate and mobile phase compositions and pH. It was observed that the small changes in these operational parameters did not lead to changes of retention time of the peak interest. The degree of reproducibility of the results has proven that the method is robust and the data are summarized in [ Table 5 ]. The ruggedness of the method was determined by carrying out the experiment on different instrument like Waters HPLC and Shimadzu HPLC and by two different operators using different columns of similar type like Phenomenex C 18 ,HypersilC 18 and the results were shown in [Table 6 ],the low RSD values confirms the ruggedness of the method.
Estimation of cefixime and moxepril in tablet dosage form Twenty tablets of each brand Suprax® and Moxif®were weighed individually and ground to a fine powder. An accurately weighed powder sample equivalent to 100 mg of both CEF and MOX were transferred to 100 ml of volumetric flask 
CONCLUSION
The developed method is accurate, simple, economical, rapid and selective for the simultaneous estimation of cefixime and moxifloxacin in bulk and in tablet dosage form without prior separation. The excipients of the commercial sample analyzed did not interfere in the analysis, which proved the specificity of the method for these drugs. The sample preparation is simple,the analysis time is short and the elution is isocratic.Hence, the proposed method can be conveniently adopted for the routine quality control analysis in the combination formulations.
